Candriam S.C.A. Has $14.02 Million Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Candriam S.C.A. decreased its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 2.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 731,221 shares of the company’s stock after selling 18,583 shares during the quarter. Candriam S.C.A. owned approximately 0.92% of Viridian Therapeutics worth $14,018,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in VRDN. Raymond James Financial Inc. acquired a new position in shares of Viridian Therapeutics during the 4th quarter worth about $6,015,000. Arizona State Retirement System raised its holdings in Viridian Therapeutics by 19.5% during the fourth quarter. Arizona State Retirement System now owns 16,596 shares of the company’s stock worth $318,000 after acquiring an additional 2,708 shares in the last quarter. Victory Capital Management Inc. acquired a new position in Viridian Therapeutics during the fourth quarter valued at approximately $7,868,000. Charles Schwab Investment Management Inc. boosted its position in Viridian Therapeutics by 11.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 575,070 shares of the company’s stock valued at $11,024,000 after purchasing an additional 58,857 shares during the last quarter. Finally, Fisher Asset Management LLC grew its stake in Viridian Therapeutics by 4.7% in the fourth quarter. Fisher Asset Management LLC now owns 518,027 shares of the company’s stock valued at $9,931,000 after purchasing an additional 23,103 shares in the last quarter.

Analyst Ratings Changes

VRDN has been the subject of several recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a report on Monday, December 16th. Needham & Company LLC reiterated a “buy” rating and set a $38.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. TD Cowen started coverage on shares of Viridian Therapeutics in a research note on Monday, November 25th. They issued a “buy” rating for the company. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $27.00 price objective (down from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Finally, Royal Bank of Canada upped their price target on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a report on Tuesday, December 17th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $35.70.

Viridian Therapeutics Price Performance

Shares of NASDAQ VRDN opened at $15.88 on Friday. Viridian Therapeutics, Inc. has a twelve month low of $11.40 and a twelve month high of $27.20. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $1.26 billion, a P/E ratio of -3.68 and a beta of 1.05. The stock’s 50-day simple moving average is $17.86 and its two-hundred day simple moving average is $19.64.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.24. The business had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. As a group, equities analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.